**Guidance on Aprepitant**

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

<table>
<thead>
<tr>
<th>Active ingredient:</th>
<th>Aprepitant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Form/Route:</td>
<td>Capsules/Oral</td>
</tr>
<tr>
<td>Recommended studies:</td>
<td>2 studies</td>
</tr>
</tbody>
</table>

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-way crossover *in-vivo*  
   **Strength:** 125 mg  
   **Subjects:** Normal healthy males and females, general population  
   **Additional Comments:**

2. **Type of study:** Fed  
   **Design:** Single-dose, two-way crossover *in-vivo*  
   **Strength:** 125 mg  
   **Subjects:** Normal healthy males and females, general population  
   **Additional comments:**

**Analytes to measure (in appropriate biological fluid):** Aprepitant in plasma

**Bioequivalence based on (90% CI):** Aprepitant

**Waiver request of in-vivo testing:** 40 mg and 80 mg based on (i) acceptable bioequivalence studies on the 125 mg strength, (ii) proportionally similar to the 125 mg strength, and (iii) acceptable in vitro dissolution testing.

**Dissolution test method and sampling times:**

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at [http://www.fda.gov/cder/ogd/index.htm](http://www.fda.gov/cder/ogd/index.htm). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

*Finalized May 2008*